Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, announced it has entered into a definitive agreement to be acquired by AstraZeneca.
PharmaBlock Sciences, Inc. has announced the successful attainment of Energy Management System Certification for its headquarters and R&D center in Nanjing, as well as its manufacturing facilities in Zhejiang and Shandong, China.
PharmaBlock Obtained ISO 50001 Certification, Advancing Sustainable Development Read More »
LegoChem Biosciences, Inc. announced on December 22 that it has entered into a license agreement with Janssen Biotech, Inc., a Johnson & Johnson company, to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate.
LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC Read More »
Syncell, a life science technology company known for pioneering next-generation spatial proteomics, is pleased to announce the inauguration of its US main office in Watertown, Massachusetts.
Syncell Expands Into the United States With a New Office in Watertown, MA Read More »
Asieris Pharmaceuticals announced that its product, APL-2301, used for the treatment of Acinetobacter baumannii infections, was approved for Phase I clinical trials in Australia.
Changchun GeneScience Pharmaceutical, a subsidiary of Changchun High-Tech Industries, held a groundbreaking ceremony for its new global headquarters and research & development center at Shanghai Zhangjiang International Medical Park on December 15th.
GenSci Launches Global Innovation Hub in Shanghai Read More »
Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for Part 1 of the New Drug Application for dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and
The innovative development of biopharmaceuticals has ushered in a new era for disease treatment, bringing unprecedented hope to countless patients.
Debería recomendarse: “al menos 3 horas al día de actividad física ligera”
Este es el curioso aspecto del cúmulo estelar NGC 2264, apodado “el Cúmulo Árbol de Navidad. Su forma recuerda claramente a la parte superior de un árbol navideño. Además, el modo en que se tomó la fotografía, incluyendo en colores falsos …
